Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter prospective single arm phase II study. The purpose of this study is to
evaluate the safety and efficiency of azacytidine combined with chidamide in the treatment of
relapsed/refractory angioimmunoblastic T-cell lymphoma.